Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: The influence of polysorbate 60 and 80

European Journal of Pharmaceutical Sciences

Volumn 35, Issue 3, 2008, Pages 211-218

  Lind, Marianne L ^a   Jacobsen, Jette ^a   Holm, René ^b   Müllertz, Anette ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

Author keywords

Cycloheximide; Halofantrine; Intestinal lymphatic transport; Polysorbate; Rat

Indexed keywords

CHYLOMICRON; CYCLOHEXIMIDE; HALOFANTRINE; POLYSORBATE 60; POLYSORBATE 80; SODIUM CHLORIDE; SOYBEAN OIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CANNULATION; CHYLOMICRON FLOW BLOCKING; CIRCULATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TRANSPORT; FEEDING; INTESTINE LYMPH; MALE; MAXIMUM PLASMA CONCENTRATION; MESENTERY LYMPH NODE; NONHUMAN; PARAMETER; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIMALARIALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHYLOMICRONS; CYCLOHEXIMIDE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; INTESTINES; LYMPHATIC SYSTEM; MALE; PHENANTHRENES; POLYSORBATES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SOYBEAN OIL; SURFACE-ACTIVE AGENTS;

EID: 50449093858     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.07.003     Document Type: Article

References (27)

1. Bergstedt S.E., Hayashi H., Kritchevsky D., and Tso P. A comparison of absorption of glycerol tristearate and glycerol trioleate by rat small intestine. Am. J. Physiol. 259 (1990) G386-G393
2. Bernard A., Carlier H., and Caselli C. Biochemical and ultrastructural study of actidione-cycloheximide effect on fat intestinal absorption in the rat (author's transl.). J. Physiol. (Paris) 76 (1980) 147-157
3. Borén J., Rustaeus S., and Olofsson S.O. Studies on the assembly of apolipoprotein B-100- and B-48-containing very low density lipoproteins in McA-RH7777 cells. J. Biol. Chem. 269 (1994) 25879-25888
4. Caliph S.M., Charman W.N., and Porter C.J.H. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J. Pharm. Sci. 89 (2000) 1073-1084
5. Charman W.N.A., and Stella V.J. Effect of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT. Int. J. Pharm. 33 (1986) 165-172
6. Charman W.N.A., Noguchi T., and Stella V.J. An experimental system designed to study the in situ intestinal lymphatic transport of lipophilic drugs in anesthetized rats. Int. J. Pharm. 33 (1986) 155-164
7. Charman W.N.A., Noguchi T., and Stella V.J. Testing potential dosage form strategies for intestinal lymphatic drug transport: studies in the rat. Int. J. Pharm. 33 (1986) 173-179
8. Dahan A., and Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur. J. Pharm. Sci. 24 (2005) 381-388
9. Field F.J., Albright E., and Mathur S.N. Regulation of triglyceride-rich lipoprotein secretion by fatty acids in CaCo-2 cells. J. Lipid Res. 29 (1988) 1427-1437
10. Hauss D.J., Fogal S.E., Ficorilli J.V., Price C.A., Roy T., Jayaraj A.A., and Keirns J.J. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J. Pharm. Sci. 87 (1998) 164-169
11. Holm R., Müllertz A., Christensen E., Høy C.E., and Kristensen H.G. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. Eur. J. Pharm. Sci. 14 (2001) 331-337
12. Holm R., Porter C.J.H., Müllertz A., Kristensen H.G., and Charman W.N. Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats. Pharm. Res. 19 (2002) 1354-1361
13. Humberstone A.J., Currie G.J., Porter C.J.H., Scanlon M.J., and Charman W.N. A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions. J. Pharm. Biomed. Anal. 13 (1995) 265-272
14. Karpf D.M., Holm R., Kristensen H.G., and Müllertz A. Influence of the type of surfactant and the degree of dispersion on the lymphatic transport of halofantrine in conscious rats. Pharm. Res. 21 (2004) 1413-1418
15. Lind M.L., Jacobsen J., Holm R., and Müllertz A. Development of simulated intestinal fluids containing nutrients as transport media in the Caco-2 cell culture model: Assessment of cell viability, monolayer integrity and transport of a poorly aqueous soluble drug and a substrate of efflux mechanisms. Eur. J. Pharm. Sci. 32 (2007) 261-270
16. O'Driscoll C.M. Lipid-based formulations for intestinal lymphatic delivery. Eur. J. Pharm. Sci. 15 (2002) 405-415
17. Porter C.J.H., and Charman W.N. Intestinal lymphatic drug transport: an update. Adv. Drug Deliv. Rev. 50 (2001) 61-80
18. Porter C.J.H., Charman S.A., and Charman W.N. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. J. Pharm. Sci. 85 (1996) 351-356
19. Porter C.J.H., Charman S.A., Humberstone A.J., and Charman W.N. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. J. Pharm. Sci. 85 (1996) 357-361
20. Porter C.J.H., Trevaskis N.L., and Charman W.N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 6 (2007) 231-248
21. Pouton C.W. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. 29 (2006) 278-287
22. Sabesin S.M., and Isselbacher K.J. Protein synthesis inhibition: mechanism for the production of impaired fat absorption. Science 147 (1965) 1149-1151
23. Seeballuck F., Lawless E., Ashford M.B., and O'Driscoll C.M. Stimulation of triglyceride-rich lipoprotein secretion by polysorbate 80: in vitro and in vivo correlation using Caco-2 cells and a cannulated rat intestinal lymphatic model. Pharm. Res. 21 (2004) 2320-2326
24. Sitrin M.D., Pollack K.L., Bolt M.J.G., and Rosenberg I.H. Comparison of vitamin D and 25-hydroxyvitamin D absorption in the rat. Am. J. Physiol. 242 (1982) G326-G332
25. Tso P., and Balint J.A. Formation and transport of chylomicrons by enterocytes to the lymphatics. Am. J. Physiol. 250 (1986) G715-G726
26. van Greevenbroek M.M.J., van Meer G., Erkelens D.W., and de Bruin T.W.A. Effects of saturated, mono-, and polyunsaturated fatty acids on the secretion of apo B containing lipoproteins by Caco-2 cells. Atherosclerosis 121 (1996) 139-150
27. van Greevenbroek M.M.J., Erkelens D.W., and de Bruin T.W.A. Caco-2 cells secrete two independent classes of lipoproteins with distinct density: effect of the ratio of unsaturated to saturated fatty acid. Atherosclerosis 149 (2000) 25-31